MREO
Income statement / Annual
Last year (2023), Mereo BioPharma Group plc's total revenue was $10.00 M,
an increase of 563.57% from the previous year.
In 2023, Mereo BioPharma Group plc's net income was -$29.47 M.
See Mereo BioPharma Group plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$10.00 M
|
$1.51 M
|
$36.46 M
|
$393,000.00
|
-$122,000.00
|
$0.00
|
-$3.29 M
|
$0.00
|
| Cost of Revenue |
$2.57 M |
$936,000.00 |
$17.91 M |
$16.35 M |
$23.61 M |
$22.70 M |
$34.61 M |
$24.56 M |
| Gross Profit |
$7.43 M |
$571,000.00 |
$18.56 M |
-$15.95 M |
-$23.73 M |
-$22.70 M |
-$37.89 M |
-$24.56 M |
| Gross Profit Ratio |
0.74 |
0.38 |
0.51 |
-40.6 |
194.51 |
0 |
11.53 |
0 |
| Research and Development
Expenses |
$17.42 M
|
$24.96 M
|
$23.56 M
|
-$16.35 M
|
-$23.61 M
|
$22.70 M
|
$34.61 M
|
$24.56 M
|
| General & Administrative
Expenses |
$18.42 M
|
$19.54 M
|
$15.93 M
|
$21.22 M
|
$15.91 M
|
$12.50 M
|
$10.70 M
|
$11.62 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$18.42 M
|
$19.54 M
|
$15.93 M
|
$21.22 M
|
$15.91 M
|
$12.50 M
|
$10.70 M
|
$11.62 M
|
| Other Expenses |
-$10,000.00 |
$811,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$293,328.00 |
$0.00 |
| Operating Expenses |
$34.56 M |
$44.51 M |
$39.49 M |
$21.22 M |
$15.91 M |
$12.50 M |
$10.70 M |
$11.62 M |
| Cost And Expenses |
$37.14 M |
$43.57 M |
$57.40 M |
$37.57 M |
$39.52 M |
$35.21 M |
$45.30 M |
$36.18 M |
| Interest Income |
$2.13 M |
$696,000.00 |
$1,000.00 |
$44,000.00 |
$377,000.00 |
$306,831.00 |
$826,855.00 |
$195,141.00 |
| Interest Expense |
$2.88 M |
$3.36 M |
$4.00 M |
$6.38 M |
$3.50 M |
$2.36 M |
$1.09 M |
$179,765.00 |
| Depreciation &
Amortization |
$1.06 M
|
$1.51 M
|
$866,466.00
|
$44,000.00
|
$1.95 M
|
$37,796.00
|
$36,076.00
|
$32,940.00
|
| EBITDA |
-$23.95 M
|
-$42.06 M
|
-$20.31 M
|
-$37.53 M
|
-$37.56 M
|
-$34.86 M
|
-$44.44 M
|
-$38.41 M
|
| EBITDA Ratio |
-2.4 |
-27.91 |
-0.56 |
-95.48 |
307.89 |
0 |
13.53 |
0 |
| Operating Income Ratio
|
-2.84
|
-28.91
|
-0.57
|
-95.6
|
323.91
|
0
|
13.79
|
0
|
| Total Other
Income/Expenses Net |
-$2.11 M
|
$7.48 M
|
$35.18 M
|
-$128.88 M
|
-$1.60 M
|
-$43,863.00
|
-$1.38 M
|
$2.26 M
|
| Income Before Tax |
-$30.00 M |
-$36.09 M |
$14.24 M |
-$166.45 M |
-$41.12 M |
-$37.31 M |
-$46.95 M |
-$33.72 M |
| Income Before Tax Ratio
|
-3
|
-23.95
|
0.39
|
-423.54
|
337.03
|
0
|
14.29
|
0
|
| Income Tax Expense |
-$532,000.00 |
-$1.90 M |
$1.52 M |
-$2.82 M |
-$6.27 M |
-$5.28 M |
-$8.15 M |
-$5.33 M |
| Net Income |
-$29.47 M |
-$34.20 M |
$12.73 M |
-$163.63 M |
-$34.84 M |
-$32.03 M |
-$38.80 M |
-$28.39 M |
| Net Income Ratio |
-2.95 |
-22.69 |
0.35 |
-416.36 |
285.61 |
0 |
11.81 |
0 |
| EPS |
-0.0447 |
-0.0567 |
0.0241 |
-0.48 |
-0.39 |
-0.45 |
-0.56 |
-0.63 |
| EPS Diluted |
-0.0447 |
-0.0567 |
0.0229 |
-0.48 |
-0.39 |
-0.45 |
-0.56 |
-0.63 |
| Weighted Average Shares
Out |
$659.45 M
|
$603.20 M
|
$527.82 M
|
$337.72 M
|
$89.34 M
|
$71.14 M
|
$69.01 M
|
$44.79 M
|
| Weighted Average Shares
Out Diluted |
$659.45 M
|
$603.20 M
|
$555.28 M
|
$338.95 M
|
$89.42 M
|
$71.14 M
|
$69.01 M
|
$44.79 M
|
| Link |
|
|
|
|
|
|
|
|
